Spyre Therapeutics, Inc. (SYRE)
Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data
Spyre Therapeutics is building a long-acting antibody platform across IBD and rheumatology. However, they only have Phase 2 assets, with SPY001 and SPY002 that recently showed encouraging Part A data. We still need to wait to see their placebo-controlled data, as well as their combo therapy data.
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today
Spyre Therapeutics SYRE has given investors a classic biotech dilemma. The pipeline is advancing, the cash balance is large and the stock has already moved sharply higher.
Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts
Spyre Therapeutics SYRE has become a closely watched clinical-stage biotech stock as investors look ahead to a busy stretch of data readouts that could define the company's next phase. The company is focused on inflammatory bowel disease, or IBD, where it is developing long-acting antibodies and antibody combinations aimed at improving disease control, convenience and durability of response.
SYRE and Spyre Ride New IBD Trends in Biotech Drug Design
SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.
Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset
Spyre is building a modular immunology platform targeting IBD and rheumatic diseases with internally developed, long-acting antibody combinations. Positive Phase 2 data for SPY001 and SPY002 in ulcerative colitis validate SYRE's approach, with a third monotherapy readout and multiple rheumatology catalysts expected in 2026. SYRE's $1.18B cash position funds operations into 2H 2029, supporting robust clinical execution and mitigating near-term dilution risk.
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up
Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.
SYRE Stock Jumps More Than 70% in a Month: What Is Driving This Rally?
Spyre Therapeutics' stock rises 73% in a month after mid-stage data show strong efficacy and safety for SPY001 in ulcerative colitis, boosting investor optimism.
Spyre Therapeutics: Strong SPY001 Data Set Up A Catalyst-Rich 2026
Spyre Therapeutics delivered strong Phase 2 data for SPY001, showing rapid, deep efficacy and a clean safety profile in ulcerative colitis. SPY001 achieved a 9.2-point RHI reduction, 40% clinical remission, and 51% endoscopic improvement at 12 weeks, suggesting best-in-class potential. Valuation reflects high expectations for SPY001 and combination regimens, with a $3-4B enterprise value and significant premium for future innovation.
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Spyre Therapeutics, Inc. (SYRE) Discusses SPY001 Part A Induction Topline Results From SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Transcript
Spyre: 'Strong Buy' As UC Program Moves Along And Q3 2026 RA Data Looms
Spyre Therapeutics, Inc. receives a Strong Buy rating, driven by positive phase 1 data and robust pipeline progress in IBD and rheumatic diseases. SPY001 demonstrated a half-life 4x greater than ENTYVIO, supporting quarterly or twice-yearly dosing for ulcerative colitis in the ongoing phase 2 SKYLINE trial. Accelerated recruitment in the phase 2 SKYWAY RA sub-study brings the anti-TL1A SPY072 data readout forward to Q3 2026, enhancing SYRE's near-term catalysts.
Spyre Therapeutics, Inc. $SYRE Shares Bought by B Group Inc.
B Group Inc. increased its holdings in Spyre Therapeutics, Inc. (NASDAQ: SYRE) by 25.0% in the undefined quarter, according to its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company's stock after buying an additional 20,000 shares during the period. Spyre Therapeutics comprises approximately 1.3% of B
